Chugai Pharmaceutical plans to build new Antibody API Manufacturing plant at Ukima Plant, Tokyo

Specifications:

Name:

Chugai Pharmaceutical plans to build new Antibody API Manufacturing plant at Ukima Plant, Tokyo

Location:

Tokyo

Company:

Chugai Pharmaceutical

Estimated Cost:

-

Source:

chugai-pharm.co.jp

Introduction:

Chugai Pharmaceutical announced plans to construct a new plant for manufacturing antibody active pharmaceutical ingredients (API) at the Ukima Plant (Kita-ku, Tokyo) of Chugai Pharma Manufacturing Co., Ltd., a manufacturing subsidiary of the company.

Features:

This new plant for manufacturing antibody active pharmaceutical ingredients (API) capable of high-mix low-volume production for late-stage investigational drugs and initial commercial products at the Ukima Plant. Chugai is aiming to possess global top-class competitiveness by minimizing the time required from the development to launch of a new drug by handling the simultaneous development of multiple products.

With this capital investment, six 6,000 L bioreactor tanks will be newly installed. Combined with the existing two 2,500 L tanks and four 2,000 L tanks, the Ukima Plant will have a total capacity of 49,000 L bioreactor tanks, with a consistent system from process development to production of antibody API of investigational drugs in late-stage clinical studies and initial commercial products at one site.

Overview of Construction Plan of Antibody API Production Plant at Ukima Plant

• Start of Construction: January 2016
• Completion of Construction: December, 2017
• Total Investment: 37.2 billion yen
• Completion of Building: July, 2018
• Start of Operation: June, 2019
• Total Floor Area: 26,634 m²